Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cann… Read more
Abattis Bioceuticals Corp (ATTBF) - Total Assets
Latest total assets as of September 2019: $19.26 Million USD
Based on the latest financial reports, Abattis Bioceuticals Corp (ATTBF) holds total assets worth $19.26 Million USD as of September 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abattis Bioceuticals Corp - Total Assets Trend (2008–2019)
This chart illustrates how Abattis Bioceuticals Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abattis Bioceuticals Corp - Asset Composition Analysis
Current Asset Composition (September 2019)
Abattis Bioceuticals Corp's total assets of $19.26 Million consist of 18.7% current assets and 81.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.5% |
| Accounts Receivable | $155.08K | 0.8% |
| Inventory | $267.82K | 1.4% |
| Property, Plant & Equipment | $756.98K | 3.9% |
| Intangible Assets | $11.69 Million | 60.7% |
| Goodwill | $3.16 Million | 16.4% |
Asset Composition Trend (2008–2019)
This chart illustrates how Abattis Bioceuticals Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abattis Bioceuticals Corp's current assets represent 18.7% of total assets in 2019, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2019, down from 100.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 76.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 60.7% of total assets.
Abattis Bioceuticals Corp Competitors by Total Assets
Key competitors of Abattis Bioceuticals Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Abattis Bioceuticals Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Abattis Bioceuticals Corp generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Abattis Bioceuticals Corp is currently not profitable relative to its asset base.
Abattis Bioceuticals Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.73 | 34.51 | 0.94 |
| Quick Ratio | 0.68 | 34.41 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.31 Million | $ 10.16 Million | $ -74.89K |
Abattis Bioceuticals Corp - Advanced Valuation Insights
This section examines the relationship between Abattis Bioceuticals Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.38 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 69.0% |
| Total Assets | $19.26 Million |
| Market Capitalization | $14.33K USD |
Valuation Analysis
Below Book Valuation: The market values Abattis Bioceuticals Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Abattis Bioceuticals Corp's assets grew by 69.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abattis Bioceuticals Corp (2008–2019)
The table below shows the annual total assets of Abattis Bioceuticals Corp from 2008 to 2019.
| Year | Total Assets | Change |
|---|---|---|
| 2019-09-30 | $19.26 Million | +68.97% |
| 2018-09-30 | $11.40 Million | +841.44% |
| 2017-09-30 | $1.21 Million | -4.47% |
| 2016-09-30 | $1.27 Million | -21.45% |
| 2015-09-30 | $1.61 Million | -72.67% |
| 2014-09-30 | $5.90 Million | +262.34% |
| 2013-09-30 | $1.63 Million | +22.97% |
| 2012-09-30 | $1.33 Million | +84.53% |
| 2011-09-30 | $718.06K | -11.63% |
| 2010-09-30 | $812.61K | +8.14% |
| 2009-09-30 | $751.43K | +357725.24% |
| 2008-09-30 | $210.00 | -- |